Drug intelligence / Profile preview

metformin + vildagliptin (Alfa Pharma)

Development stage
Unknown
Lead developer
Alfa Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Vildatin Plus is a fixed-dose combination generic drug containing the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin and the biguanide antihyperglycemic agent metformin hydrochloride. Marketed by Alfa Pharma and manufactured by Celogen Pharma, it is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control in adults. Vildagliptin works by inhibiting the DPP-4 enzyme, which prevents the degradation of incretin hormones like GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin hydrochloride works primarily by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these complementary mechanisms provide superior glycemic control compared to either monotherapy.

Brand names
EucreasGalvus MetGalvumetIcandraVildatin MVildatin PlusZomarist
Other names
metformin hydrochloride + vildagliptinvildagliptin + metforminvildagliptin + metformin hydrochloridevildagliptin/metformin
02

Targets

DPP9 (Dipeptidyl Peptidase 9)AMPK (Adenosine monophosphate–activated protein kinase)GSEC (Gamma-Secretase Complex)DPP8 (Dipeptidyl peptidase 8)GPD2 (Glycerol-3-phosphate dehydrogenase 2)ND1 (Mitochondrial electron transport chain complex I)FAP (Fibroblast activation protein alpha)DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on metformin + vildagliptin (Alfa Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + vildagliptin (Alfa Pharma).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call